Lung Diseases - HLBS-PopOmics -

Main|Search|PHGKB




Last Posted: Nov 01, 2019

---

• Are liquid biopsies a surrogate for tissue EGFR testing?
  Goldman J W et al. Annals of oncology : official journal of the European Society for Medical Oncology 2018 29(suppl_1) i38-i46
• NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.
  Ettinger David S et al. Journal of the National Comprehensive Cancer Network : JNCCN 2018 16(7) 807-821
• Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational Status.
  Kim Hayeon et al. American journal of clinical oncology 2019 Nov 42(11) 837-844
• Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
  Wang Yu et al. Japanese journal of clinical oncology 2019 Oct
• EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs.
  Liang Zhiyong et al. Cancer letters 2017 403186-194
• Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
  Husain Aliya Noor et al. Archives of pathology & laboratory medicine 2018 Jan 142(1) 89-108
• Understanding Precision Medicine And AI Within The Life Cycle Of Technology Revolutions
  D Shaywitz, Forbes, October 16, 2019
• Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
  Garrido P et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2019 Oct
• Brief Report: Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.
  Mikubo Masashi et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019 Oct
• Programmed Death-Ligand 1 and Vimentin: A Tandem Marker as Prognostic Factor in NSCLC.
  Ancel Julien et al. Cancers 2019 Sep 11(10)

more